|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPARgamma.
|
9734398 |
1998 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We report here that PPAR-gamma ligands dramatically attenuate cytokine gene expression in colon cancer cell lines by inhibiting the activation of nuclear factor-kappaB via an IkappaB-alpha-dependent mechanism.
|
10449430 |
1999 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor (PPAR) gamma is expressed in human colon cancer, prostate cancer and breast cancer cells, and PPARgamma activation induces growth inhibition in these cells.
|
11044367 |
2000 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR-gamma), a member of the nuclear hormone receptor superfamily, is involved in suppression of growth of several types of tumors such as liposarcoma, breast cancer, prostate cancer, and colon cancer, possibly through induction of cell cycle arrest and/or apoptosis.
|
11494023 |
2001 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present results suggest the potential usefulness of PPARgamma ligands for chemoprevention and treatment of colon cancers.
|
11950812 |
2002 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study suggested that a PPARgamma-Bcl-2 feedback loop may function to control the life-death continuum in colonic cells and that a deficiency in generation of PPARgamma ligands may precede the development of human colon cancer.
|
12269390 |
2002 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
This finding suggests a potentially important use for PPARgamma ligands as chemopreventative agents in colon cancer.
|
12370429 |
2002 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand that has pro-apoptotic activity in human colon cancer.
|
12475986 |
2003 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, only retroviral transduction of the wild-type (WT), but not mutant, receptor could restore PPARgamma ligand-induced growth inhibition and differentiation in resistant colon cancer cell lines.
|
12591919 |
2003 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The activation of peroxisome proliferator-activated receptor gamma stimulated by thiazolidinedione is useful in the treatment of type II diabetes mellitus and may have value in preventing inflammatory bowel disease or colon cancer.
|
12946210 |
2003 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.
|
12946234 |
2003 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone.
|
14634802 |
2004 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
To better understand their role, we studied the expression levels of all PPAR-isoforms and transcriptional partners such as the retinoid X receptor alpha (RXRalpha) and PPARgamma-coactivator-1 (PGC-1) by means of real-time PCR in 17 patients with colon cancer.
|
14670614 |
2004 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the nuclear receptor superfamily, plays a role in adipocyte differentiation, type II diabetes, macrophage response to inflammation and is suggested to influence carcinogen-induced colon cancer.
|
15073042 |
2004 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The molecules and signals that act to eradicate or initiate the apoptosis cascade in cancer cells, are elucidated, and these include caspases, Fas, Bax, Bid, APC, antisense hTERT, PUMA, 15-LOX-1, ceramide, butyrate, tributyrin and PPARgamma, whereas the molecules which promote colon cancer cell survival are p53 mutants, Bcl-2, Neu3 and COX-2.
|
15255176 |
2004 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'indolyl)-1-(p-substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF)), p-t-butyl (DIM-C-pPhtBu), and p-phenyl (DIM-C-pPhC6H5) groups induce peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated transactivation in HT-29, HCT-15, RKO, and SW480 colon cancer cell lines.
|
15342379 |
2004 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, PPARgamma protein levels are elevated, possibly through sequestration by activated beta-catenin in colon cancer cell lines.
|
15665104 |
2005 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The odd ratio for PPARgamma PA or AA genotype relative to the PP genotype for colon cancer was 0.9 (95% confidence interval, CI=0.8-1.0) and for rectal cancer was 1.2 (95% CI=1.0-1.5) adjusting for race, age, and sex.
|
15860437 |
2005 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
High lutein intake [odds ratio (OR), 0.63; 95% confidence interval (95% CI), 0.44-0.89], low refined grain intake (OR, 0.70; 95% CI, 0.53-0.94), or a high prudent diet score (OR, 0.66; 95% CI, 0.49-0.89) and PA/AA PPARgamma genotype were associated with reduced colon cancer risk.
|
15894676 |
2005 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
We can therefore exclude this alteration as a mechanism of resistance to PPAR(gamma) ligands in patients with colon cancer.
|
15911106 |
2005 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1.
|
16155208 |
2005 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
To elucidate cdk5's role in PPARgamma ligand-induced antiproliferation of colon cancer cells, HT-29 cells were treated with ciglitazone.
|
16327995 |
2006 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
There was a significant interaction between the -200A>C IGFBP3 polymorphism and the Pro12Ala PPARgamma polymorphism and risk of colon cancer (p for interaction = 0.02) with individuals being at significantly lower risk if they had both the CC IGFBP3 genotype and the PA/AA PPARgamma genotype.
|
16489531 |
2006 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Based on our findings, p38 MAPK and transcription factor PPARgamma can be considered as molecular targets of resveratrol in the regulation of cell proliferation and SSAT activity, respectively, in a cell culture model of colon cancer.
|
16849586 |
2006 |